MedTrace Logo

Esketamine on Postpartum Depression in Cesarean Section Women

NCT04860661 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 336

Last updated 2024-08-06

No results posted yet for this study

Summary

This study was to explore the preventive effect of esketamine on postpartum depression (PPD) in cesarean section, and to evaluate the safety of the drug

Conditions

Interventions

DRUG

Esketamine

After delivery, the parturient was given a loading dose of esketamine, and then a small dose of esketamine was added into PCIA analgesia pump

DRUG

Normal saline

10 ml normal saline

Sponsors & Collaborators

  • Maternal and Child Health Hospital of Hubei Province

    collaborator OTHER

  • Jingmen No.1 People's Hospital

    collaborator OTHER

  • Ailin Luo

    lead OTHER

Principal Investigators

  • Ailin luo, Dr. · Department of Anesthesiology of Tongji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2024-03-31
Completion
2024-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04860661 on ClinicalTrials.gov